Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D (UST1D)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02117765 |
Recruitment Status : Unknown
Verified May 2016 by University of British Columbia.
Recruitment status was: Active, not recruiting
First Posted : April 21, 2014
Last Update Posted : May 25, 2016
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Drug: Ustekinumab | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes |
Study Start Date : | March 2015 |
Estimated Primary Completion Date : | February 2017 |
Estimated Study Completion Date : | June 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment
Four cohorts of 5 subjects will be recruited: Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks. Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks. Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks. Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks. |
Drug: Ustekinumab
Other Name: Stelara |
- Primary Safety Endpoints (composite outcome measure) [ Time Frame: 12 months ]
- Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome.
- Vital signs, standard hematology and chemistry tests, physical examinations.
- Immunological Endpoints (composite outcome measure) [ Time Frame: 12 months ]
- Immune phenotyping via flow cytometry of all Interleukin (IL)-12, IL-23, IL-17, Interferon(IFN)-γ secreting immune subsets.
- Basic immune phenotyping of white blood cell subsets.
- Human leukocyte antigen(HLA)- A, B, C, DR, DP, DQ typing.
- Fluorospot (ELISpot) analysis for IL-17 and IFN-γ secretion in response to whole insulin and antigens for Cluster of differentiation (CD)8+ and CD4+ T cells .
- Luminex assessment of serum cytokines IL-17, IFN-γ, IL-12 and IL-23.
- Regulatory T cell : Effector T cell ratio
- CD154 based assays to determine diabetogenic antigen specific responses of T helper cells.
- Epigenetic assessment of Treg phenotype and function.
- Exploratory (composite outcome measure) [ Time Frame: 12 months ]
- Mixed-meal tolerance test (MMTT) - stimulated 2-hour C-peptide area under the curve (AUC) at weeks 4, 28 and 52.
- Insulin use in units per kg body weight per day at weeks 4, 16, 28, 40 and 52.
- HbA1C levels at weeks 4, 16, 28, 40 and 52.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 35 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- A diagnosis of type 1 diabetes mellitus in accordance with the canadian diabetes association criteria.
- An interval of ≤100 days between the diagnosis and the first dose of the study drug
- Ability to provide documented informed consent.
- Male or female, aged 18-35 years inclusive, at the time of the anticipated first dose of the study drug.
- Evidence of residual functioning β cells. This will be assessed by a C-peptide level over 0.2nmol/L in the MMTT test.
- Positive for at least one diabetes-related autoantibody.
- Willing to record all insulin taken and blood glucose levels that are required for monitoring during the study, including reporting any hypoglycaemic events.
Exclusion Criteria:
- No condition that, in the investigators' judgment, is likely to cause the subject to not be able to understand information in order to provide informed consent.
- History of malignancy.
- No significant and/or active disease in any body system that is likely to increase the risk to the subject or interfere with the subject's participation in the study.
- No significant systemic infection during the 6 weeks before the first dose of the study drug.
- No history of current or past active tuberculosis infection and no latent tuberculosis.
- Have used any other investigational drug within the 3 months prior to the first dose and/or intend on using any investigational drug for the duration of the study.
- Prior or current treatment that is known to cause a significant, ongoing change in the course of T1D or immunological status.
- Current or prior (within 30 days prior to first study drug dose) use of medications known to influence glucose tolerance.
- No significant abnormal laboratory values during the screening period, other than those due to T1D.
- Not pregnant, breastfeeding or planning to become pregnant during the 60 days after the last dose of the study drug.
- Have not received any live vaccines within 30 days prior to the first study drug dose and are not expected to need to receive a vaccine during the study.
- No prior allergic reaction, including anaphylaxis, to any component of the study drug product.
- No prior allergic reaction, including anaphylaxis, to any human, humanized, chimeric or rodent antibody treatment.
- Have not undergone any major surgery within the 30 day period prior to the first drug dose and not anticipating requiring surgery during the study period.
- Negative results for Hepatitis B surface antigen and for antibodies to Hepatitis B core antigen, or evidence of Hepatitis B surface antibody > 10 IU, and negative for Hepatitis C. Negative results for HIV and not considered by the investigator to be at high risk for HIV infection.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02117765
Canada, British Columbia | |
BC Diabetes | |
Vancouver, British Columbia, Canada, V5Z 1M9 |
Principal Investigator: | Jan Dutz, MD FRCPC | Professor Department of Dermatology and Skin Science University of British Columbia | |
Study Director: | Ashish Marwaha, BMBCh PhD | University of British Columbia | |
Study Director: | Annika Sun, MSc | University of British Columbia |
Responsible Party: | University of British Columbia |
ClinicalTrials.gov Identifier: | NCT02117765 |
Other Study ID Numbers: |
H14-00939 |
First Posted: | April 21, 2014 Key Record Dates |
Last Update Posted: | May 25, 2016 |
Last Verified: | May 2016 |
T1D ustekinumab new-onset diabetes |
Diabetes Mellitus, Type 1 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Autoimmune Diseases Immune System Diseases Ustekinumab Dermatologic Agents |